Log in to save to my catalogue

Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-la...

Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-la...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2735382619

Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study

About this item

Full title

Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study

Publisher

England: BMJ Publishing Group Ltd and European League Against Rheumatism

Journal title

Annals of the rheumatic diseases, 2022-12, Vol.81 (12), p.1750-1756

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group Ltd and European League Against Rheumatism

More information

Scope and Contents

Contents

ObjectivesPatients under rituximab therapy are at high risk for a severe COVID-19 disease course. Humoral immune responses to SARS-CoV-2 vaccination are vastly diminished in B-cell-depleted patients, even after a third vaccine dose. However, it remains unclear whether these patients benefit from a fourth vaccination and whether continued rituximab...

Alternative Titles

Full title

Immunogenicity and safety of a fourth COVID-19 vaccination in rituximab-treated patients: an open-label extension study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2735382619

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2735382619

Other Identifiers

ISSN

0003-4967

E-ISSN

1468-2060

DOI

10.1136/ard-2022-222579

How to access this item